R&D ea Sorrento e tsepamisitse maikutlo ho nts'etsopele ea boqapi ho COVID-19, kalafo ea mofets'e, taolo e felletseng ea bohloko le mafu a autoimmune.

Mananeo a Bohlokwa	Tlhaloso	Pele ho tlhokomelo	Karolo ea I	Mothati oa II	Mokhahlelo oa III/Bohlokoa	FDA Approval
Mananeo a COVID-19
COVISTIX™ (tlhahlobo) Tlhahlobo e potlakileng ea Antigen 0%* Tumello ea Tšebeliso ea Tšohanyetso (EUA) Mexico (COFEPRIS), Brazil (ANVISA), le CE E tšoauoa Europe COVIMARK™ (tlhahlobo) Tlhahlobo e potlakileng ea Antigen 0%* Kopo e rometsoe US le Canada bakeng sa Tumello ea Tšebeliso ea Tšohanyetso (EUA) COVISHIELD™ (kalafo) Antibody e Neutraizing (IN) ho Bakuli ba ka Ntle le Bakuli ba ka Lapeng 40%* COVISHIELD™ (kalafo) Antibody e Neutralizing (IV) ho Bakuli ba ka Ntle le Bakuli ba ka Lapeng 20%* FUJOVEE™ (Abivertinib) COVID-19 e matla ho Bakuli ba ICU 82%* Teko ea Bohlokoa e Emetseng ho Hlakoloa ha FDA OQORY™ (COVI-MSC) ARDS ka lebaka la COVID-19 ho Bakuli ba ICU 82%* Teko ea Bohlokoa Brazil Mlan Inhibitor (pilisi ea molomo) Khahlano le bongata 40%* Ente ea Omicron mRNA ente 20%*
Mananeo a Bohlokwa	Tlhaloso	Pele ho tlhokomelo	Karolo ea I	Mothati oa II	Mokhahlelo oa III/Bohlokoa	FDA Approval
immunotherapy
FUJOVEE™ (Abivertinib) NSCLC 82%* FUJOVEE™ (Abivertinib) B Cell Lymphomas 60.2%* FUJOVEE™ (Abivertinib) Prostate 20%* FUJOVEE™ (Abivertinib) Lupus 20%* FUJOVEE™ (Abivertinib) MS 20%* FUJOVEE™ (Abivertinib) GvHD 20%* PD-L1 (Socazolimab)* SCLC 82%* *Ka Tšebelisano le Lee's Pharm naheng ea China PD-L1 (STI-3031)** Kankere ea Mokokotlo 82%* **Naheng ea Amerika le ka kopanelo le ImmuneOncia ea Korea CD47 Lihlahala tse Tiileng 40%* CD38 DAR-T Myeloma e ngata 40%* CD38 ADC Amyloidosis, Multiple Myeloma, T-ALL, le esophageal 40%* TROP2 ADC* Lihlahala tse Tiileng 40%* * China Seprehvec™ oncolytic virus Lihlahala Tse Tiileng; Lihlahala tsa CNS 40%* BCMA ADC Lihlahala tsa Metsi 20%* Bevacizumab-ADAB™ Kankere ea Endometrial 40%* Ka kopanelo le Mayo Clinic Bevacizumab-ADAB™ Cancer ea kankere ea mahe 40%* Ka kopanelo le Mayo Clinic Rituximab-ADAB™ B-cell Lymphomas 40%* Ka kopanelo le Mayo Clinic
Mananeo a Bohlokwa	Tlhaloso	Pele ho tlhokomelo	Karolo ea I	Mothati oa II	Mokhahlelo oa III/Bohlokoa	FDA Approval
Bohloko
ZTlido™ 1.8% Neuralgia ea Postherpetic - PHN 99.8%* Sp,-102 (SEMDEXA) Bohloko ba Lumbar Radicular / Sciatica 82%* Sp,-103 (Lidocaine Topical System 5.4%) Mahlaba a Acute Back Back 20%* Sp,-104 (Naltrexone e Liehisitsoe ho Burst Low) Fibromyalgia 20%* RTX (resiniferatoxin) Epidural ente Bohloko bo ke keng ba Rarolloa ho Kankere e Tsoetseng Pele 60.3%* Lebitso la khutsana RTX (resiniferatoxin) Tsela e ka hare-hare Bohloko bo Itekanetseng ho isa ho Bohlokoa Knee 60.2%*
Mananeo a Bohlokwa	Tlhaloso	Pele ho tlhokomelo	Karolo ea I	Mothati oa II	Mokhahlelo oa III/Bohlokoa	FDA Approval
Phaliso ea Lymphatic
Sofusa® -ba khahlanong le TNF Autoimmune (RA) 40%* Sofusa® anti-PD-1 Cutaneous T-Cell Lymphoma (CTCL) 40%* Sofusa® khahlanong le CTLA-4 Melanoma 40%* Ka kopanelo le Mayo Clinic

Mananeo a COVID-19
Mananeo a Bohlokwa (Tlhahiso)	Phase
COVISTIX™ (tlhahlobo) FDA EUA COVIMARK™ (tlhahlobo) FDA EUA COVISHIELD™ (kalafo) PH I COVISHIELD™ (kalafo) Pele ho tlhokomelo FUJOVEE™ (Abivertinib) Ph III OQORY™ (COVI-MSC) Ph III Mpro Inhibitor (pilisi ea molomo) (anti-viral) Ph I Ente ea Omicron mRNA (ente) Pele ho tlhokomelo

immunotherapy
Mananeo a Bohlokwa (Tlhahiso)	Phase
FUJOVEE™ (Abivertinib) (NSCLC) Ph III FUJOVEE™ (Abivertinib) (B Cell Lymphomas) Ph II FUJOVEE™ (Abivertinib) (Prostate) Pele ho tlhokomelo FUJOVEE™ (Abivertinib) (Lupus) Pele ho tlhokomelo FUJOVEE™ (Abivertinib) (MOF) Pele ho tlhokomelo FUJOVEE™ (Abivertinib) (GvHD) Pele ho tlhokomelo PD-L1 (Socazolimab)*(SCLC) Ph III PD-L1 (STI-3031)** (Kankere ea popelo) Ph III CD47 (Lihlahala tse tiileng) Ph I CD38 DAR-T Myeloma e ngata Ph I CD38 ADC (Amyloidosis, Multiple Myeloma, T-ALL, le esophageal) Ph I TROP2 ADC* (Lihlahala tse tiileng) Ph I Seprehvec™ oncolytic virus (Lihlahala tse tiileng; CNS Tumors) PH I BCMA ADC (Lihlahala tsa Metsi) Pele ho tlhokomelo Bevacizumab-ADAB™ (Kankere ea Endometrial) Ph I Bevacizumab-ADAB™ (Kankere ea Ovary) Ph I Rituximab-ADAB™ (B-cell Lymphomas) Ph I

Bohloko
Mananeo a Bohlokwa (Tlhahiso)	Phase
ZTlido™ 1.8% (Postherpetic Neuralgia - PHN) FDA Approval Sp,-102 (SEMDEXA) Ph III Sp,-103 (Lidocaine Topical System 5.4%) Pele ho tlhokomelo Sp,-104 (Naltrexone e Liehisitsoe ho Burst Low) Pele ho tlhokomelo RTX (resiniferatoxin) Epidural ente (Bohloko bo ke keng ba Batla Kankere e Tsoetseng Pele) Ph II RTX (resiniferatoxin) Tsela e ka hare-hare (Mahlaba a Knee Mangoleng a Bohareng ho isa ho a Matenya) Ph II

Phaliso ea Lymphatic
Mananeo a Bohlokwa (Tlhahiso)	Mothati oa II
Sofusa® -ba khahlanong le TNF (Autoimmune RA) Ph I Sofusa® anti-PD-1 T-Cell Lymphoma (CTCL) Ph I Sofusa® khahlanong le CTLA-4 (Melanoma) Ph I